· Mainboard · NSE, BSE
Price Band
₹768–807
Lot Size
18 shares
Issue Size
₹940 Cr
Min. Investment
₹14,526
Indicative, updates through the day
Cap price plus current GMP: ₹923 — arithmetic, not a forecast
Molbio Diagnostics IPO is a Mainboard issue that listed on NSE, BSE on 17 August 2026. The issue price band is fixed at ₹768–₹807 per equity share with a minimum market lot size of 18 shares, bringing the total issue size to ₹940 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹14,526.
The latest unlisted Grey Market Premium (GMP) for Molbio Diagnostics IPO is quoted at ₹116, representing a premium of approximately 14.37% over the upper price band of ₹807. On a simple cap price plus GMP basis, the estimated opening price indicates a listing near ₹923, and informal quotes have risen over recent sessions. Please note that GMP is an unregulated sentiment indicator quoted by off-market dealers; it fluctuates based on supply-demand dynamics and does not constitute a guaranteed listing price. For historical accuracy studies, read our research on IPO GMP accuracy, or compare with live GMP quotes for all active IPOs.
As per the latest exchange feeds from BSE and NSE, Molbio Diagnostics IPO has been subscribed 70.18x overall — with QIB at 186.39x, NII at 49.77x, bNII at 50.82x, sNII at 47.69x, Retail at 12.8x, Employee at 13.14x, representing over 26,54,105 retail and institutional applications. When the retail category is oversubscribed, SEBI regulations mandate that allotment is determined via an automated computerized lottery where each valid PAN gets one equal chance.
The minimum investment for retail investors is one lot of 18 shares (approx. ₹14,526 at the cut-off price), while the maximum retail bid is capped at 13 lots (under ₹2,00,000). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is KFin Technologies Ltd., with the basis of allotment finalised on 13 August 2026 and listing completed on 17 August 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹807
Listed At
₹980
Current Price
₹1041.7
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
Molbio Diagnostics IPO raises ₹281.46 crore from anchor investors. Molbio Diagnostics IPO Anchor bid date is August 7, 2026.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 58,12,862 | 50% |
| − Anchor Investor | 34,87,717 | 0% |
| − QIB (Ex. Anchor) | 23,25,145 | 0% |
| NII (HNI) | 17,43,860 | 15% |
| − bNII > ₹10L | 11,62,573 | 0% |
| − sNII < ₹10L | 5,81,287 | 0% |
| Retail | 40,69,005 | 35% |
| Employee | 20,519 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1242 | ₹10,02,294 |
EPS (Pre IPO)
14.56
EPS (Post IPO)
14.24
ROE
14.55%
P/E (Pre IPO)
55.43
P/E (Post IPO)
56.67
Price / Book
Market Cap
₹9,099.71 Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Fabtech Technologies Ltd. | 13.32 | ₹230.30 Cr | |
| Q-Line Biotech Ltd. | 20.82 | ₹214.48 Cr | |
| Earkart Ltd. | 20.48 | ₹49.26 Cr | |
| Galaxy Medicare Ltd. | 19.01 | ₹22.31 Cr |
Molbio Diagnostics Ltd. Address
KFin Technologies Ltd.